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ABSTRACT
Objectives: To  determine the incidence of port-site
metastases in patients undergoing laparoscopic proce-
dures for gynecologic cancers.
Methods: The charts of patients treated by laparoscopy
for diagnosis, treatment, or staging of gynecologic can-
cers by the academic faculty attending physicians were
studied from July 1, 1997 to June 30, 2001. No patient
without a histological or cytological diagnosis of cancer
from the index procedure were included. Fisher’s exact
test was used for statistical analysis.
Results: Eighty-three patients were identified accounting
for 87 procedures. Types of cancer treated included
endometrial (39), ovarian (29), and cervical (14). Twenty
procedures were performed for recurrence of ovarian or
peritoneal cancer, and ascites was present in 10 cases.
Port-site metastases occurred in 2 patients accounting for
8 sites. Five sites were diagnosed in a single patient 13
days after a second-look laparoscopy for stage IIIB ovar-
ian cancer, and 3 sites were diagnosed in a patient 46
days after an interval laparoscopy for stage IIIC primary
peritoneal cancer. Ascites was present in both patients.
The overall incidences of port-site metastases per proce-
dure and per port placed were 2.3% (2/87) and 2.4%
(8/330), respectively. In patients with a recurrence of
ovarian or peritoneal cancer, no port-site metastases
(0/16) occurred in the absence of ascites, whereas 50%
(2/4) of patients with ascites developed port-site metas-
tases (P<.035).
Conclusions: The overall incidence of port-site metastases
in gynecologic cancers in our study was 2.3%. The risk of
port-site metastases is highest (50%) in patients with recur-
rence of ovarian or primary peritoneal malignancies under-
going procedures in the presence of ascites.
INTRODUCTION
The first detailed descriptions of the use of laparoscopy
in the management and treatment of patients with gyne-
cologic cancers were reported approximately 30 years
ago.1-3 Since that time, an increasing number of
advanced laparoscopic techniques have been used in the
management of gynecologic malignancies including sec-
ond-look laparoscopy, laparoscopic lymphadenectomy,
laparoscopically assisted vaginal hysterectomy, and
laparoscopically assisted radical vaginal hysterectomy.4-6
Although these techniques generally aim to perform the
identical surgery that would be performed through a tra-
ditional laparotomy incision, the use of laparoscopy in
cancer patients has introduced unique complications and
risks in these patients. In particular, an increasing
amount of literature describes postoperative tumor
growth at the specific puncture sites associated with tro-
car placement.7 In fact, cases of port-site metastases have
been reported involving cancers of the ovary,8-17
cervix,15,18-22 endometrium,23 fallopian tube,24 and vagi-
na16 as well as nongynecologic cancers including stom-
ach, gallbladder, large bowel, liver, pancreas, and urinary
tract.7
While the case reports of port-site metastases in patients
with gynecologic malignancies continue to accumulate in
the literature, the true incidence of this phenomenon has
not been clearly defined. For example, 3 studies that
have specifically addressed this issue have demonstrated
a wide range in reported incidence. Childers et al12
reported port-site metastases in 1 of 88 patients (1.4% per
procedure) undergoing a laparoscopic procedure for
ovarian cancer and 1% per procedure for gynecologic
cancers in general, while Kruitwagen et al13 reported the
incidence of port-site metastases to be 16% in patients
with ovarian cancer undergoing laparoscopic procedures
9 to 35 days prior to the initial debulking procedure.
Finally, van Dam et al17 reported port-site metastases in
9% of patients (9/104) undergoing laparoscopic proce-
dures for primary or recurrent ovarian cancer.
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The importance of defining the rate at which port-site
metastases occurs has become paramount given the
increasing number of gynecologic oncologists who are
utilizing laparoscopy in the treatment and management of
their patients. Furthermore, if specific risk factors can be
identified, this information could be used to help define
which patients would most likely benefit from the laparo-
scopic approach. Therefore, we sought to determine the
incidence of port-site metastases in patients undergoing
laparoscopic procedures for gynecologic malignancies
and to define which patients are at highest risk for the
development of this phenomenon.
METHODS
The charts of patients treated by laparoscopy for diagno-
sis, treatment, or staging of gynecologic cancers by the
academic faculty attending physicians were studied from
July 1, 1997 to June 30, 2001. Eligible patients were iden-
tified by reviewing the fellows’ case lists and medical
records. No patient without a histological or cytological
diagnosis of cancer from the index procedure was includ-
ed. For the cases identified, charts were reviewed for
information regarding the patient’s age at the time of the
procedure, the date of the procedure, and the types of
surgeries performed. Information was also collected on
the types of malignancies encountered (including histo-
logic subtypes, grade, stage, and recurrence). The
method of laparoscopic entry (ie, direct entry, open
entry, or Veress needle entry) was recorded, as well as
the number, size, and location of ports at each surgery.
Charts were reviewed for the most recent follow-up and
for the development of postoperative port-site metas-
tases.
In general, multipuncture operative laparoscopy was per-
formed with the patient under general endotracheal
anesthesia by using <15 mm Hg CO2 gas for the creation
of a pneumoperitoneum.4 A gynecologic oncology
attending physician and a gynecologic oncology fellow
were present at each procedure.
All information collected was placed into a computerized
database using Microsoft Access 2000 software. Statistical
analysis was performed using Fisher’s exact test.
RESULTS
Of the 84 patients identified, insufficient information was
available on 1 case. Therefore, 83 patients accounting for
87 procedures provided the basis for this study (Table
1). The mean age of patients at the time of surgery was
58 years (range, 38 to 93). Procedures included
Table 1.
Characteristics of Cancers*
Site Number  Stage Ascites Port-site  Metastases
I,II,III,IV Cases (No.of Sites)
Endometrium 39 32,2,5,0 1 0
Primary 37 31,2,4,0 1 0
Recurrent 2 1,0,1,0 0 0
Ovarian Epithelium 29 6,1,20,2 7 0
Primary 10 5,1,2,2 4 0
Recurrent 19 1,0,18,0 3 1(5)
Cervix 14 6,6,0,2 2 0
Primary 12 6,4,0,2 2 0
Recurrent 2 0,2,0,0 0 0
Sarcoma of Uterus or Ovary 3-00
Primary 1 - 0 0
Recurrent 2 - 0 0
Metastatic Breast 2 0,0,0,2 0 0
Fallopian Tube 2 1,1,0,0 0 0
Primary Peritoneum Recurrent 1 0,0,1,0 1 1(3)
*One patient had a synchronous ovarian and endometrial cancer, and two patients had a synchronous ovarian and cervical cancer.
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node removal (n=42). Types of cancer treated included
endometrial (39), epithelial ovarian (29), cervical (14),
sarcomas (uterine or ovarian) (3), metastatic breast (2),
fallopian tube (2), and primary peritoneal (1). One
patient had a synchronous ovarian and endometrial can-
cer, and 2 patients had a synchronous ovarian and cervi-
cal cancer. Endometrioid adenocarcinoma (n=38) and
papillary serous adenocarcinoma (n=27) were the most
common histological subtypes noted. Forty-three percent
of procedures were performed for grade 3 malignancies,
and ascites was present in 10 cases. Laparoscopic entry
types included 58 direct entries, 18 open entries, and 11
Veress needle entries. In the 87 procedures, 330 trocar
sites were described, and conversion to laparotomy was
elected in 18 cases. The average period of follow-up was
361 days (range, 17 to 1282). Port-site metastases occur-
red in 2 patients accounting for 8 sites as described
below.
Port-Site Metastases Cases
Patient 1 was a 56-year-old female who had a history of
stage IIIC papillary serous, poorly differentiated, primary
peritoneal cancer. Her initial staging procedure included
an exploratory laparotomy, total abdominal hysterecto-
my, bilateral salpingo-oophorectomy, bilateral pelvic and
para-aortic lymph node sampling, omentectomy, and
optimal debulking. Postoperatively, she received 10
cycles of chemotherapy with paclitaxel and carboplatin.
Approximately 11 months after the initial procedure, the
patient underwent an open interval laparoscopy, aspira-
tion of ascites, multiple biopsies and partial peritonecto-
my. This procedure used a 10-mm infraumbilical port, a
5-mm port in the left upper quadrant, a 5-mm port in the
right mid abdomen, and 5-mm bilateral lower quadrant
ports. Findings at the time of surgery included approxi-
mately 1000 mL of ascites and multiple nodules measur-
ing up to 3 mm scattered throughout the abdomen and
pelvis. All residual disease at the completion of the sur-
gery was less than 1 cm. Final pathology from this pro-
cedure confirmed poorly differentiated adenocarcin-
oma  involving peritoneal and omental im-
plants. Postoperatively, the patient began second-line
chemo-therapy with liposomal doxorubicin and gemc-
itibine. Forty-six days after the interval laparoscopy (at
the time of the second cycle of chemotherapy), this
patient was noted to have abdominal wall metastases at
the location of the left upper quadrant, umbilicus, and
JSLS(2004)8:133-139 135
right mid-abdominal wall. Port-site metastases can be
clearly seen on the computed tomography scan of the
abdomen and pelvis (Figure 1). The patient was given
the option of surgical resection of the tumor prior to radi-
ation treatment, but elected to proceed with radiation
therapy alone. She received 3000 cGy of radiation thera-
py to the affected sites with gradual improvement in the
abdominal wall masses noted on clinical examination.
Shortly after completing her radiation treatment, the
patient transferred her care to Puerto Rico and expired 6
weeks later.
Patient 2 was a 59-year-old female with a history of stage
IIIB poorly differentiated papillary serous adenocarcino-
ma of the ovary. Her initial staging procedure included
an exploratory laparotomy, total abdominal hysterecto-
my, bilateral salpingo-oophorectomy, appendectomy,
cholecystectomy, sigmoid resection and reanastomosis,
and suboptimal debulking (1/4 inch of tumor carpeting
the pelvic floor was not removed). Postoperatively, the
patient received 6 cycles of topotecan and cisplatin fol-
lowed by a second-look laparoscopy with multiple biop-
sies. For this procedure, a Veress needle was placed in
the left upper quadrant, and a pneumoperitoneum was
created. A spinal needle was used to map the anterior
Figure 1. CT scan of the abdomen and pelvis demonstrating
port-site metastases at the umbilical and right lateral locations
in Patient 1 following a recent laparoscopic procedure.
Lateral Trocar
Site Implant
Umbilical Trocar
Site Implant
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abdominal wall, a clear space was determined just above
the umbilicus, and a 5-mm trocar was placed at this posi-
tion. Five-millimeter trocars were also placed at the
suprapubic region, bilateral lower quadrants, and in the
left upper quadrant for a total of 5 trocars used in this
procedure. Findings at the time of surgery included
approximately 150 mL of murky ascites, several small 1-
mm nodules studding the diaphragm, and multiple nod-
ules (< 5 mm) lining the pelvic floor and bilateral pelvic
sidewalls. At the completion of the procedure, the
remaining disease was not greater than 2 mm at its great-
est diameter throughout the abdomen and pelvis. The
final pathology from this procedure showed adenocarci-
noma consistent with ovarian origin involving the vaginal
cuff, abdominal wall, and cul-de-sac adhesions. Thirteen
days after her second-look laparoscopy, the patient pre-
sented with areas of swelling at all 5 laparoscopic inci-
sions consistent with port-site metastases. She was admit-
ted to the hospital for a partial small bowel obstruction,
and subsequently underwent an examination under anes-
thesia, diagnostic laparoscopy, exploratory laparotomy,
tumor biopsy, aspiration of ascites, and ileotransverse
colon bypass. Findings at the time of surgery included
approximately 4 liters of ascites and diffuse carcinomato-
sis. The rectosigmoid colon was severely attached to the
pelvic sidewall, the terminal ileum, and the cecum. Bulky
tumor in this area was found to be the cause of the
obstruction. Entry into the abdomen was initially accom-
plished using an open laparoscopic approach, and a sec-
ond 5-mm trocar was placed in the midline lower
abdomen. The ascites was removed, and the decision
was made to proceed with a laparotomy via a vertical
midline incision to perform a small bowel to trans-
verse colon bypass. Postopera-tively, the patient
received 8 cycles of paclitaxel, adriamycin, and cisplatin,
and remained clinically free of disease for approximately
5 months. She then showed evidence of recurrence and
received 4 cycles of liposomal doxorubicin and gemcitib-
ine followed by excision of a right lower quadrant ante-
rior abdominal wall mass. Based on chemosensitivity
results performed on the tumor, the patient then received
8 cycles of 5-fluorouracil with leucovorin. She was found
to have brain metastases during this treatment, and she
died of her disease approximately 3 weeks after her
eighth cycle of 5-fluorouracil with leucovorin.
Incidence of Port-Site Metastases
The overall incidences of port-site metastases per proce-
dure and per port placed were 2.3% (2/87) and 2.4%
(8/330), respectively. The incidence of port-site metas-
tases per procedure for cancer of the ovary, peritoneum,
and fallopian tube was 6.25% (2/32). Twenty procedures
were performed for recurrence of ovarian or peritoneal
cancer, and the specific characteristics of these cases are
summarized in Table 2. Of these 20 procedures, ascites
was present in 4 cases. In patients with recurrence of
ovarian or peritoneal cancer (Table 3), no port-site
metastases (0/16) occurred in the absence of ascites,
whereas 50% (2/4) of patients with ascites developed
port-site metastases (P<.035).
DISCUSSION
The overall incidence of port-site metastases in gyneco-
logic cancers in our study was 2.3%. Our results demon-
strate that the risk of port-site metastases was 50% in
patients undergoing laparoscopic procedures for recur-
rence of ovarian or primary peritoneal malignancies in
the presence of ascites.
The association of ascites with port-site metastases after
laparoscopy was initially described in 1978 in a patient
with ovarian cancer.8 Since that report, several
authors7,11,13,16,17 have suggested that the presence of
ascites may be a contraindication to performing
laparoscopy in patients with known or suspected malig-
nancy. Specifically, a review of the literature of all cases of
port-site metastases demonstrated the presence of ascites to
be significantly associated with the early occurrence of port-
site metastases,7 and another study has demonstrated that
patients with ovarian cancer who developed port-site
metastases after undergoing laparoscopy tended to have
larger amounts of ascitic fluid present at the time of sur-
gery.17 Although our numbers are small, our results sup-
port the notion that the presence of ascites in patients
with known or suspected malignancies may be associat-
ed with the development of trocar site metastases post-
operatively.
While second-look laparoscopies are being performed
more and more frequently in patients with ovarian can-
cer, the safety of this procedure is still under investiga-
tion. Both cases of port-site metastases in our experience
occurred in patients after undergoing a second-look or
interval laparoscopy, which suggests that patients with
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with primary disease. Although at least 3 cases of port-
site metastases following a second-look (or third-look)
laparoscopy for ovarian cancer have been report-
ed,12,16,25 over 25 cases of port-site metastases have been
reported in the English literature in patients after
laparoscopy for primary ovarian cancer.8-11,13-17 It is pos-
sible that the number of port-site metastases in patients
following interval laparoscopies has been underreported
and that as this procedure continues to be more widely
accepted, further cases will be identified. We have shown
that patients undergoing laparoscopic procedures for
recurrence of ovarian and primary peritoneal cancer in
the presence of ascites have a significantly higher risk of
developing port-site metastases compared with patients
without ascites.
Although the concept of tumor cell contamination of the
surgical wound was described over 40 years ago,26 the
mechanism by which wound metastases occurs is still
not completely understood. Several factors related to sur-
gery have been implemented in aiding the spread of can-
cer cells including accidental incision of the tumor, tran-
section of lymphatic channels that contain cancer, direct
dissemination of surface tumors, and even the biological
conditions created by the trauma of surgery itself. Many
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theories have been proposed to account for the ability of
tumor to spread to surgical wounds. For example, the
tumor cell entrapment hypothesis, which was proposed
in 1989, suggests that free cancer cells are able to implant
on raw tissue surfaces including damaged peritoneal sur-
faces.27 Postoperatively, these areas become covered by
a fibrinous exudate which could serve to protect the
tumor cells from destruction by the normal defense
mechanisms. The tumor cell entrapment hypothesis is
supported by studies that have demonstrated tumor cells
at concentrations of up to 26% in wound washings and
have shown the recovery of tumor cells from the gloves
and instruments used during surgery.26 Hypotheses spe-
cific to laparoscopy include exfoliation and spread of
tumor cells by laparoscopic instruments, direct implanta-
tion at the trocar site by frequent changes of instruments,
direct implantation from the passage of the specimen,
the presence of the pneumoperitoneum, which can cre-
ate a “chimney effect” that causes an increase in the pas-
sage of tumor cells at port-sites, and preferential growth
of malignant cells at areas of laparoscopic peritoneal per-
foration.7 Interestingly, a recent case report describes a
patient who underwent an exploratory laparotomy with
optimal cytoreduction and postoperative platinum-based
chemotherapy for stage IIIC ovarian cancer, who later
presented with recurrence in an operative incision from
a laparoscopic cholecystectomy that had been performed
several months prior to her initial cancer diagnosis.28
This case further underscores the complexity of the
mechanisms involved in the occurrence of port-site
metastases.
Currently, investigators are researching ways to prevent
tumor spread during laparoscopy and several clinical
reports have suggested that gasless laparoscopy may aid
in the prevention of port-site metastases by reducing
tumor dissemination created by the CO2 pneumoperi-
toneum.7,16,29 However, in vitro research involving a
Table 2.
Characteristics of Recurrent Epithelial Ovarian and Primary
Peritoneal Cancers/Surgical Procedures
Factor Number
Ascites
Absent 16
Present 4
Histological Subtype
Papillary Serous 18
Clear Cell 1
Not Available 1
Grade
10
21
31 8
Not Available 1
Entry Type
Direct 9
Open 7
Veress Needle 4
Laparotomy
Yes 8
No 12
Table 3. 
Observed Frequencies of Port-Site Metastases and
Ascites in Patients With Recurrent Epithelial
Ovarian and Primary Peritoneal Cancers
Ascites Port-Site Port-Site
Metastases Absent Metastases Present
Absent 16 0
Present 2 2
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laparoscopic model performed on colorectal cancer cells
showed that malignant cells were not identified in the
CO2 exhaust, but were found on the laparoscopic instru-
ments used.30 Similarly, a study of the instruments, tro-
cars, and CO2 gas of 12 patients undergoing staging
laparoscopy for pancreatic cancer showed extremely low
levels of free-floating tumor cells when compared with
the cell content found on the trocars and instruments.31
In both cases, the authors concluded that the finding of
malignant cells on the ports was a result of direct con-
tamination by the instruments and not from dispersion of
malignant cells by the CO2 gas. Finally, in a recent
prospective randomized study in rats using a xenograft
ovarian cancer model, port-site metastases was found to
be significantly higher in the gasless laparoscopy group
compared with that in a group that had laparoscopy with
a CO2 pneumoperitoneum.32 Whether or not patients
with malignancy would benefit from a gasless
laparoscopy approach remains controversial and further
research is needed in this area.
In addition to the perceived increased frequency of
wound metastases to port-sites compared with patients
undergoing traditional laparotomy procedures, the vast
majority of reported cases suggests a much more rapid
recurrence of tumor in patients with port-site metastases.
In a study that reviewed the literature for all cases of port-
site metastases (including 20 cases involving gynecologic
malignancies), the period of time from the procedure to
the diagnosis of port-site metastases ranged from 7 days
to 3 years, and in general gynecologic cancers had a
shorter interval to occurrence than other reported can-
cers.7 Specific factors that were shown to be significantly
associated with the rapid development of port-site metas-
tases postoperatively included the diagnosis of ovarian
malignancy, the presence of ascites, and noncurative sur-
gery. Our findings are consistent with those described
above as our patients (one with ovarian cancer and one
with primary peritoneal cancer) developed port-site
metastases at 13 days and 46 days postoperatively after
undergoing noncurative procedures in the presence of
ascites.
Several studies have suggested possible methods to avoid
or decrease the occurrence of port-site metastases in
addition to the ways outlined above. The use of intraperi-
toneal cytotoxic agents at the time of laparoscopy is cur-
rently under investigation, and one study33 has shown a
significant reduction in port-site metastases when diluted
povidone-iodine was instilled in the peritoneal cavity in a
rat model. The early onset of postoperative chemothera-
py has been advocated by several authors that have sug-
gested that patients with a longer duration between
laparoscopy and postoperative chemotherapy may be
more likely to develop port-site metastases.14,15,17
Irrigation of the port-sites has been recommended7,12,14,17
as well as the use of specimen bags to remove tissues in
which malignancy is suspected.17 Authors have suggest-
ed that diagnostic or palliative procedures, or both, be
avoided, and whenever possible a comprehensive
cytoreductive procedure be performed.7,14,17 In terms of
wound closure, a recent study17 demonstrated fewer
cases of port-site metastases in patients that had the
wound closed in layers (peritoneum, rectus fascia, and
skin) compared with patients who only had the skin
closed. Whether any or all of these recommendations
prove to help decrease the rate of port-site metastases
remains to be seen.
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